An interventional study of Standard Duodenal Switch and Single Anastomosis Duodenal Switch in Obesity and Morbid Obesity, sponsored by Laval University. Recruiting at 1 site in Canada. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2024-08-09.
Sponsored by Laval University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 32 studies in Obesity, Morbid with a site in Canada — 7 open to participants now, 10 under way, none of them phase 3. Obesity, Morbid · Canada.
Among the 32 studies in Obesity, Morbid with a site in Canada, this one is the 4th largest by planned enrollment of the 22 interventional ones that give a count, is one of 2 that started in 2015, is one of 17 with no phase, and was the 19th registered.
941 studies on the registry are indexed under Obesity, Morbid; 162 are open to participants now.
Browse Obesity, Morbid studies →7 of the 32 studies in Obesity, Morbid with a site in Canada are open now. Recruiting first, the newest first:
Laval University · Sites in Canada
Ages 18–65
Laval University · Sites in Canada
Ages 18–60
CHU de Quebec-Universite Laval · Sites in Canada
Ages 18+
Nova Scotia Health Authority · Sites in Canada
Ages 18–65 · Healthy volunteers
CHU de Quebec-Universite Laval · Sites in Canada
Ages 18–60 · Healthy volunteers
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 109 Obesity, Morbid studies recruiting now, 21 (19%) set no upper age limit and 83 (76%) stop at 75 or younger; 8 take children under 18; 9 take healthy volunteers.
This study: 18 Years to 60 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
32 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 2 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 120 is above the median of 62 across 601 interventional studies indexed under Obesity, Morbid.
Median enrollment 57 across the 22 interventional studies, 145 across the 10 observational. Of the 18 that completed or were terminated, 7 (39%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 32 have an industry lead sponsor. The 10 most frequent:
Laval University is the lead sponsor of 380 studies on the registry; 67 are open to participants now.
Laval University has 9 studies filed under Obesity, Morbid — fewer than ten, so there is no comparison to draw.
3 of the studies in Obesity, Morbid with a site in Canada that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05242835Laval UniversityManagement of Sleeve Gastrectomy Failure Using Single-anastomosis Metabolic Surgery | 2027-01 |
| NCT05120492Nova Scotia Health AuthorityOptimal Management of Extreme Obesity and Severe Knee Osteoarthritis Feasibility Trial | 2027-07 |
| NCT06002906University Health Network, TorontoThe Use of Indocyanine Green to Visualize Blood Flow to the Gastrojejunostomy During Bariatric Surgery. | 2027-07-03 |
Add all 3 to your calendar (.ics) → With an account.
Among the 32 studies in Obesity, Morbid with a site in Canada, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Bilio-Pancreatic diversion with Duodenal Switch (BPD-DS) is the most effective bariatric procedure in terms of long-term weight loss and remission rate of Type 2 Diabetes. However, its technical difficulty and increased risk of long-term nutritional deficiencies have been a major hindrance to its diffusion.
Recently, a " simplified " technique of Duodenal-Switch has been proposed by Sanchez-Pernaute et al. This technique involves the creation of a Sleeve Gastrectomy, transection of the first duodenum, and connection of the duodenum to an omega-loop of small bowel instead of a terminal intestinal loop used in standard BPD-DS.
The overall objective of this study is to assess in a prospective randomized blinded trial, the outcomes of this new procedure, using a comprehensive clinical evaluation and follow-up method. This could potentially change the clinical practice and surgical approach in our Institution.
Bilio-Pancreatic diversion with Duodenal Switch (BPD-DS) is the most effective bariatric procedure in terms of long-term weight loss and remission rate of Type 2 Diabetes. However, its technical difficulty and increased risk of long-term nutritional deficiencies have been a major hindrance to its diffusion. Our team, with more than 4000 BPD-DS performed since the early 1990's, is recognized internationally for its expertise with this specific procedure.
Recently, a " simplified " technique of Duodenal-Switch has been proposed by Sanchez-Pernaute et al. This technique involves the creation of a Sleeve Gastrectomy, transection of the first duodenum, and connection of the duodenum to an omega-loop of small bowel instead of a terminal intestinal loop used in standard BPD-DS.
This new procedure, called Single Anastomosis Duodenal Switch has the potential benefit of decreasing the complexity of the standard BPD-DS by avoiding one of the two intestinal anastomoses usually needed. This could potentially decrease the rate of peri-operative complications and increase access to this type of surgery.
However, the length of the common channel (250cm) is more than doubled compared to standard BPD-DS, which could also change significantly the outcomes of the procedure itself. Indeed, the length of the common channel conditions the absorption of fat and fat-soluble vitamins.
Currently, the scientific literature regarding this procedure is scarce, with only one author who published his 2-years outcomes, in a cohort study of 100 patients. In addition, this report presents major limitations. In example, the length of the omega loop was increased from 200 to 250cm during the course of the study, in order to decrease the rate of protein deficiency and reoperation for malnutrition. This and other limitations make it hard to assess the actual results of the technique.
The overall objective of this study is to assess in a stronger study design (i.e. a prospective randomized single blinded trial), the outcomes of this new procedure, using a comprehensive clinical evaluation and follow-up method. This could potentially change the clinical practice and surgical approach in our Institution.
941 studies on the registry are indexed under Obesity, Morbid; 162 are open to participants now.
This study's planned enrollment of 120 is above the median of 62 across 601 interventional studies indexed under Obesity, Morbid.
Browse Obesity, Morbid studies →Laval University is the lead sponsor of 380 studies on the registry; 67 are open to participants now.
Compared within Obesity, Morbid, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Obesity. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants who meet any of the following criteria at the time of the baseline visit are excluded from the study:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biliopancreatic diversion with Duodenal Switch (BPD-DS), with Sleeve gastrectomy, including a 100cm common channel and 150cm stric alimentary limb
Procedure: Standard Duodenal Switch
Single-Anastomosis Duodeno-Ileal anastomosis (SADI) with Sleeve Gastrectomy, including a 250cm common channel
Procedure: Single Anastomosis Duodenal Switch
Also known as: BPD-DS
Also known as: SADI
Excess weight loss
Excess weight loss at 2 years of follow-up %EWL (Excess weight loss based on an ideal BMI = 25.) and change in BMI as compared to preoperative reference values
Time frame: 2 years
Rate of protein deficiency or insufficiency
Rate of protein deficiency (\<35gr/l) or insufficiency (\<30gr/l)
Time frame: from baseline up to 60 months
Mortality rate
Rate of mortality
Time frame: from baseline up to 60 months
BMI
change in BMI at 2 years follow-up as compared to preoperative reference values
Time frame: 2 years
Complication rate
overall and surgery-specific complications
Time frame: from baseline up to 60 months
Cure rate of comorbidities
Remission rate for comorbidities, including T2D, Hypertension, dyslipidemia, sleep apnea
Time frame: from baseline up to 60 months
Rate of minerals and vitamin deficiencies
Rate of deficiency and insufficiency in mineral and vitamins
Time frame: from baseline up to 60 months
Body composition by bioimpedance measures
body fat composition (%) assessed by biompedance
Time frame: from baseline up to 60 months
Change in quality of life
36-item short form survey score from 0 to 100
Time frame: from baseline up to 60 months
Change in quality of life
Bariatric Analysis and Reporting Outcomes System score from -7 to 9
Time frame: from baseline up to 60 months
Change in quality of life
Laval Questionnaire score from 0 to 7
Time frame: from baseline up to 60 months
Change in quality of life
GastroIntestinal Quality of Life Index from 0 to 144
Time frame: from baseline up to 60 months
Change in gatroesophageal reflux symptom
GastroEsophageal Reflus Disease Score from 0 to 72
Time frame: from baseline to 60 months
Plan to share: No
No publications or documents are linked to this record.
Started Sep 2015 (actual). Primary completion is estimated for Sep 2025, 120 months after the start.
Of 273 non-industry interventional studies with no phase under Obesity, Morbid, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 48. This study's planned 120 months is above that.
Counting every sponsor, half of 285 studies reached it within 25 months; a quarter within 11 and three quarters within 48.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.